Fibrinolysis in Disease - The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities , Volume 1
Crc Press Inc (Verlag)
978-0-8493-6080-0 (ISBN)
- Titel ist leider vergriffen;
keine Neuauflage - Artikel merken
Fibrinolysis in Disease reviews the state of the art of basic and clincal aspects of the fibrinolytic enzyme system. The text, authored by outstanding and internationally known investigators, is presented in two books.
The Malignant Process, Interventions in Thrombogenic Mechanisms, and Novel Treatment Modalities discuses the molecular biology of the system's key components and their fundamental roles in a variety of thrombotic and metabolic disorders. Molecular and Hemovascular Aspects of Fybrinolysis presents the latest findings and concepts of the association between plasminogen activator (u-PA) overexpression and abnormal growth regulation in a variety of solid tumors and in leukemia. One chapter deals with various successful interventions in thrombogenic mechanisms, ranging from exercise and diet to anticoagulants and direct and indirect thrombolytic agents. It concludes with a projection of exciting, novel treatment modalities in thrombotic and malignant diseases.
of The Malignant Process:
The Role of the Plasminogen Activation System in Neoplasia
uPA Production, Receptor Display, and Differentiation, D. Boyd and M. Brattain
Interactions between Epidermal Growth Factor and Its Receptor in the Regulation of Urokinase Plasminogen Activator in Normal and Malignant Keratinocytes, M.J. Niedbala and A.C. Sartorelli
Tissue-Type and Urokinase-Type Plasminogen Activators as Prognostic Markers in Breast Cancer, M.J. Duffy, D. Reilly, P. O'Grady, N. Nolan, N. O'Higgins, J.J. Fennelly, P.A. Andreasen
Both uPA and PAI-1 Are Independent Prognosticators of Relapse and Death in Breast Cancer, F. Jänicke, M. Schmitt, and H. Graeff
PAI-1 and PAI-2 Levels as Predictors in Staging Malignancy in Breast Cancer, K. Sumiyoshi, T. Urano, Y. Takada, and A. Takada
Plasminogen Activation in Ovarian Cancer, B. Casslén and B. Astedt
Increased Urokinase-Plasminogen Activator (u-PA) Expression Correlates with the Aggressive Phenotype in Human Prostate Cancer Cells, J.M. Kozlowski, H.N. Keer, F.D. Gaylis, and C. Lee
Epidermal Growth Factor Receptor and Plasminogen Activators in Bladder Cancer, D.J. Thomas and D.E. Neal
Role of u-PA in Determining the Biological Behavior of Gastric Cancer, S. Takai, M. Yamamura, S. Uetsuji, and M. Yamamoto
u-PA Levels in Plasma, Urine, and Tissues of Patients with Cancer of the Digestive Tract, N. Nishino, S. Baba, and A. Takada
u-PA:t-PA Ratio as Determinator in Gastrointestinal Cancer, H.W. Verspaget
Plasminogen Activators in Osteoblastic Cells, L.C. Carpio and R. Dziak
u-PA as an Autocrine Mitogen in Human Melanoma Cells, B.R. Binder and M. Ruthner
PAI-1 and PAI-2 in Leukemic Patients, B. Bennett and A. Croll
Interventions
Exercise
Effects of Physical Training and Smoking Cessation on PAI Levels, J.-C. Gris and J.-F. Schved
Fibrinolytic Response to Strenuous Physical Exercise, J.-B. Hansen
Diet
Hyperlipidemia and Reduced Fibrinolysis-Diet or Drugs? P. Andersen
Effect of Fish Oil on Some Parameters of Fibrinolysis, O. Haglund, T.G.P. Saldeen, and J.L. Mehta
Diet and Fibrinolysis, with Special Reference to the Effects of Fiber Intake, T.K. Nilsson, K. Boman, J.-X. Zhang, and G. Hallmans
Direct Thrombolytic Agents
Conjunctive Thrombolytic and Antithrombotic Therapy for Acute Myocardial Infarction, H.J. Rapold
Platelet Activation during Thrombolytic Therapy in Unstable Angina, M. Reilly and D.J. Fitzgerald
Paradoxic Prothrombotic Effects during Pharmacologic Thrombolysis, G.A. Ewald and P.R. Eisenberg
Plasma Fibrinopeptide A and B Levels May Not Be Specific Markers of Thrombin Activity during Pharmacologic Thrombolysis, J.I. Weitz
Efficient Coronary Thrombolysis Is Dependent on Concentrations of Free t-PA, C.L. Lucore
Thrombolytic Therapy in Patients with Acute Massive Pulmonary Embolism, M. Verstraete
Thrombolysis in Cerebrovascular Ischemia, G.J. del Zoppo
Indirect Thrombolytic Agents
Use of Ancrod in Patients with Heparin-Induced Thrombocytopenia and during Cardiopulmonary Bypass Surgery, K. Aogaichi
Therapy with Ancrod in Acute Ischemic Stroke, D.E. Levy
Fibrinolytic and Clinical Effects of Ancrod in Systemmic Lupus Erythematosus and Acute Ischemic Stroke, P. Glas-Greenwalt
Fibrinolytic Response to DDAVP and Its Potential Clinical Relevance, E. Törnebohm-Roche
Heparin and Others
Interaction of Heparin with Plasminogen Activators and Plasminogen In Vitro, D.C. Rijken, G.A.W. de Munk, and A.F.H. Jie
Profibrinolytic Effects of Modified Heparins, R. Porta and R. Pescador
Disease and Drug Modulation of Fibrinolysis, J. Fareed, P. Bacher, J.M. Walenga, D.A. Hoppensteadt, and E.W. Bermes
Future
Genetically Engineered New Thrombolytic Agents, H.R. Lijnen and D. Collen
Antibody Targeting of Plasminogen Activators, M.S. Runge, K.W. Harris, and C. Bode
The Potential Use of Anti-PAI-1 Antibodies as Adjuvants in Thrombolytic Therapy, M. Levi and B.J. Biemond
Vampire Bat Salivary Plasminogen Activator, S.J. Gardell
Stimulation of Indigenous Fibrinolysis: A Novel Approach of Prevention from Thrombosis, G. Dooijewaard and C. Kluft
The Potentials of Retinoids as Stimulators of Endogenous Tissue-Type Plasminogen Activator, T. Kooistra
Growth Factor Mechanisms and Cancer Therapy, K.R. Meehan and L.R. Zacharski
| Erscheint lt. Verlag | 12.6.1995 |
|---|---|
| Zusatzinfo | 68 Tables, black and white |
| Verlagsort | Bosa Roca |
| Sprache | englisch |
| Maße | 216 x 279 mm |
| Gewicht | 953 g |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hämatologie |
| Studium ► 1. Studienabschnitt (Vorklinik) ► Biochemie / Molekularbiologie | |
| ISBN-10 | 0-8493-6080-3 / 0849360803 |
| ISBN-13 | 978-0-8493-6080-0 / 9780849360800 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich
